Cargando…

Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies

Over the past few decades, immunotherapy has revolutionized the modern medical oncology field. Chimeric antigen receptor (CAR)-T cell therapy has a promising curative effect in the treatment of hematological malignancies. Anti-CD19 CAR-T cells are the most mature CAR-T cells recently studied and in...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Danni, Jin, Xin, Sun, Rui, Zhang, Meng, Wang, Jiaxi, Xiong, Xia, Zhang, Xiaomei, Zhao, Mingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403467/
https://www.ncbi.nlm.nih.gov/pubmed/35989682
http://dx.doi.org/10.1177/15330338221118413
_version_ 1784773383475429376
author Xie, Danni
Jin, Xin
Sun, Rui
Zhang, Meng
Wang, Jiaxi
Xiong, Xia
Zhang, Xiaomei
Zhao, Mingfeng
author_facet Xie, Danni
Jin, Xin
Sun, Rui
Zhang, Meng
Wang, Jiaxi
Xiong, Xia
Zhang, Xiaomei
Zhao, Mingfeng
author_sort Xie, Danni
collection PubMed
description Over the past few decades, immunotherapy has revolutionized the modern medical oncology field. Chimeric antigen receptor (CAR)-T cell therapy has a promising curative effect in the treatment of hematological malignancies. Anti-CD19 CAR-T cells are the most mature CAR-T cells recently studied and in recent years it has achieved a complete remission rate of approximately 90% in the treatment of B-cell acute lymphoblastic leukemia (B-ALL). Although CAR-T cell therapy has greatly alleviated the disease in patients with leukemia or lymphoma, some of them still relapse after treatment. Therefore, in this article, we discuss the factors that may contribute to disease relapse following CAR-T cell therapy and summarize potential strategies to overcome these obstacles, thus providing the possibility of improving standard treatment regimens.
format Online
Article
Text
id pubmed-9403467
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-94034672022-08-26 Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies Xie, Danni Jin, Xin Sun, Rui Zhang, Meng Wang, Jiaxi Xiong, Xia Zhang, Xiaomei Zhao, Mingfeng Technol Cancer Res Treat Advances in CAR-T Cell Therapies for Cancer Over the past few decades, immunotherapy has revolutionized the modern medical oncology field. Chimeric antigen receptor (CAR)-T cell therapy has a promising curative effect in the treatment of hematological malignancies. Anti-CD19 CAR-T cells are the most mature CAR-T cells recently studied and in recent years it has achieved a complete remission rate of approximately 90% in the treatment of B-cell acute lymphoblastic leukemia (B-ALL). Although CAR-T cell therapy has greatly alleviated the disease in patients with leukemia or lymphoma, some of them still relapse after treatment. Therefore, in this article, we discuss the factors that may contribute to disease relapse following CAR-T cell therapy and summarize potential strategies to overcome these obstacles, thus providing the possibility of improving standard treatment regimens. SAGE Publications 2022-08-22 /pmc/articles/PMC9403467/ /pubmed/35989682 http://dx.doi.org/10.1177/15330338221118413 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Advances in CAR-T Cell Therapies for Cancer
Xie, Danni
Jin, Xin
Sun, Rui
Zhang, Meng
Wang, Jiaxi
Xiong, Xia
Zhang, Xiaomei
Zhao, Mingfeng
Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
title Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
title_full Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
title_fullStr Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
title_full_unstemmed Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
title_short Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
title_sort relapse mechanism and treatment strategy after chimeric antigen receptor t-cell therapy in treating b-cell hematological malignancies
topic Advances in CAR-T Cell Therapies for Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403467/
https://www.ncbi.nlm.nih.gov/pubmed/35989682
http://dx.doi.org/10.1177/15330338221118413
work_keys_str_mv AT xiedanni relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies
AT jinxin relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies
AT sunrui relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies
AT zhangmeng relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies
AT wangjiaxi relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies
AT xiongxia relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies
AT zhangxiaomei relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies
AT zhaomingfeng relapsemechanismandtreatmentstrategyafterchimericantigenreceptortcelltherapyintreatingbcellhematologicalmalignancies